The United States Parkinson’s Disease Market size was estimated at USD 2.55 billion in 2025 and is projected to reach USD 5.51 billion by 2035, growing at a CAGR of 8.0% from 2026 to 2035. The sector has strategic importance across neurological diagnostics, medicines, neuromodulation and long-term care. An expanding patient population, improved diagnostic pathways and differentiated treatment technologies are strengthening commercial demand across healthcare providers and life sciences companies.
Key Highlights
- The South represents a major regional market, supported by its large older population, established hospital networks and demand for neurological services.
- Pharmacological treatment remains the dominant segment because levodopa-based regimens and adjunct medicines form the foundation of long-term symptom management.
- Biomarker-led diagnosis and advanced device-assisted interventions represent faster-developing areas as clinical practice moves toward earlier identification and more individualized care.
- Adaptive deep brain stimulation, continuous drug delivery and wearable monitoring are reshaping treatment personalization and ongoing patient management.
- Rising diagnosis rates, lifelong medication requirements and the need to manage motor fluctuations sustain recurring demand across medicines, devices and specialist services.
- The strongest strategic opportunity lies in connecting diagnosis, treatment selection, remote monitoring and longitudinal care into integrated patient pathways.
United States Parkinson’s Disease Market Overview
Parkinson’s disease is a progressive neurological condition that creates sustained demand across diagnosis, prescription medicines, surgical interventions, neuromodulation equipment and supportive care. The United States represents a commercially important healthcare environment because specialist neurology services, advanced hospitals, established reimbursement systems and a substantial pharmaceutical market support a broad treatment ecosystem. Demand extends beyond initial diagnosis: patients require ongoing medication adjustment, monitoring of motor and non-motor symptoms, management of complications and coordinated care as the disease advances. The Parkinson’s Foundation estimates that more than 1.1 million people in the country live with the condition, with nearly 90,000 new diagnoses annually.
Procurement decisions differ across the ecosystem. Health systems evaluate clinical evidence, device performance, procedural requirements, reimbursement and total cost of care, while pharmacies and payers assess medicine access, formulary positioning and continuity of supply. Neurology practices prioritize diagnostic confidence, treatment response and referral coordination. Deployment maturity is highest in established pharmacological treatment and conventional neuromodulation, while biomarker testing, adaptive stimulation and continuous delivery are extending the technology frontier. The United States Parkinson’s Disease Market market therefore combines mature recurring-revenue categories with specialist-led innovation opportunities. Commercial success depends on demonstrating measurable clinical value, simplifying care delivery and aligning product economics with payer and provider priorities.
Key Market Drivers & Industrial Demand Dynamics
The expanding diagnosed and treated population is a primary demand driver. Population aging increases the number of individuals entering age groups associated with higher Parkinson’s incidence, while improved clinical awareness supports earlier evaluation of tremor, rigidity, bradykinesia and related symptoms. The Parkinson’s Foundation estimates that the disease affects more than 1.1 million people in the United States and that annual new diagnoses approach 90,000.
This patient base supports sustained demand for consultations, diagnostic assessment, prescription therapies and long-term monitoring. For manufacturers, a chronic disease model creates recurring treatment requirements rather than one-time product purchases. Providers must also manage comorbidities, falls, cognitive changes and medication-related complications. Companies with broad portfolios across diagnosis, symptom control and disease management are positioned to address a larger portion of the patient journey.
Therapeutic innovation is changing treatment economics and product differentiation. Levodopa-based medicines remain central to symptom management, but wearing-off periods, dyskinesia and variable treatment response create demand for extended-release formulations, adjunct medicines and continuous delivery systems. Subcutaneous infusion products address motor fluctuations in advanced disease by providing an alternative to repeated oral dosing. Newer medicines also seek to improve symptom control through differentiated mechanisms. These advances create opportunities for pharmaceutical companies to compete through dosing convenience, tolerability, treatment persistence and clinical outcomes rather than price alone. For health systems, the operational value rests on reducing periods of inadequate symptom control and supporting individualized treatment plans. Commercial adoption depends on physician confidence, payer coverage, patient training and dependable product supply.
Device-based intervention is another important growth engine. Deep brain stimulation has an established role for selected patients with advanced motor symptoms, while adaptive stimulation introduces a more responsive approach based on neural activity. Focused ultrasound expands the procedural landscape through a non-incisional treatment option for selected symptoms and patients. These technologies require specialized clinical teams, capital equipment, procedural infrastructure and post-treatment programming. Their procurement economics therefore differ from medicine purchasing and depend on hospital investment planning, specialist availability and reimbursement pathways. Device manufacturers compete through precision, programming capabilities, sensing functions, procedural workflow and clinical support. The expansion of personalized neuromodulation strengthens demand for integrated systems that combine implanted hardware, software, clinical data and long-term service.
Diagnostic capability is gaining strategic importance as clinical research advances toward earlier and more biologically informed disease identification. Parkinson’s diagnosis continues to rely substantially on clinical assessment, but imaging, genetic testing and emerging biomarker approaches support differential diagnosis, research enrollment and patient characterization. Improved diagnostic confidence can reduce prolonged uncertainty and help clinicians select appropriate management pathways. The commercial opportunity extends to laboratory services, imaging equipment, molecular testing and specialized clinical software. However, the value of newer diagnostic tools depends on demonstrated clinical utility, reproducibility, access and integration into routine practice. Diagnostic providers must establish how test results change clinical decisions rather than relying solely on analytical performance. This creates a market advantage for companies that connect validated testing with specialist interpretation and longitudinal patient records.
The economic burden of Parkinson’s disease reinforces demand for interventions that improve care coordination and reduce avoidable complications. A 2026 report from the Michael J. Fox Foundation estimated the combined economic burden of Parkinson’s disease and atypical parkinsonism in the United States at USD 82.2 billion in 2024, including direct medical and broader indirect costs.
This burden affects patients, caregivers, employers, insurers and public programs. Health systems face pressure to improve access to movement-disorder specialists, rehabilitation and medication management. Payers increasingly assess the total cost associated with falls, hospitalizations, disability and caregiver support. Vendors that demonstrate improved continuity, reduced treatment disruption and better functional outcomes have a stronger commercial proposition than suppliers focused solely on product acquisition cost.
- ■ By Diagnosis Type
- ■ Clinical and Neurological Assessment
- ■ Structural and Functional Imaging
- ■ Molecular and Biomarker Testing
- ■ Genetic Testing
| Year | 1st QTR | 2nd QTR | 3rd QTR | 4th QTR |
|---|---|---|---|---|
| 2025 | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn |
| 2024 | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn |
| 2023 | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn | XX Mn/Bn |
| 2026 | XX Mn/Bn | 2031 | XX Mn/Bn |
| 2027 | XX Mn/Bn | 2032 | XX Mn/Bn |
| 2028 | XX Mn/Bn | 2033 | XX Mn/Bn |
| 2029 | XX Mn/Bn | 2034 | XX Mn/Bn |
| 2030 | XX Mn/Bn | 2035 | XX Mn/Bn |
Segmentation Analysis
United States Parkinson’s Disease Market, By Diagnosis Type
Diagnosis type is a distinct purchasing category because clinical practices and hospitals select diagnostic tools according to the suspected condition, differential diagnosis requirements and clinical workflow. Segments include clinical and neurological assessment, structural and functional imaging, molecular and biomarker testing, genetic testing and other diagnostic tests. Clinical assessment remains the largest segment because diagnosis and disease monitoring rely heavily on symptom history and neurological examination. Imaging supports differential diagnosis and evaluation of alternative neurological conditions, while genetic testing supports selected patients and research pathways. Molecular and biomarker testing represents a faster-developing category as research advances biological characterization. Buyers prioritize diagnostic validity, turnaround time, accessibility and compatibility with clinical records. Providers favor tests that change clinical decisions and improve referral or treatment pathways. The strongest commercial opportunity is in validated tools that complement, rather than attempt to replace, specialist assessment.
United States Parkinson’s Disease Market, By Treatment Modality
Treatment modality reflects the principal intervention purchased or delivered to manage the disease. Categories include pharmacological treatment, deep brain stimulation, focused ultrasound, infusion-based therapy and supportive and rehabilitative care. Pharmacological treatment remains the largest segment because medicines form the foundation of symptom management across disease stages. Device-assisted and procedural approaches address selected patients whose symptoms require additional intervention or whose response to medicines becomes difficult to manage. Infusion-based therapies are developing as alternatives for advanced motor fluctuations, while focused ultrasound is expanding procedural choice for appropriate candidates. Buyers evaluate clinical suitability, durability, treatment burden, adverse-event profile and reimbursement. Hospitals and specialist centers assess equipment, staffing and follow-up requirements before adopting procedural technologies. Pharmacological treatment retains broad utilization, while advanced device-assisted interventions represent a faster-developing commercial category as personalized treatment pathways mature.
United States Parkinson’s Disease Market, By Drug Class
Drug-class segmentation captures the pharmacological categories purchased by hospitals, pharmacies and patients. It includes levodopa combinations, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, adenosine A2A receptor antagonists and other drug classes. Levodopa combinations remain the largest category because of their established role in managing core motor symptoms. Adjunct therapies address wearing-off, dyskinesia and other treatment complications. Differentiated dopamine agonists and newer formulations offer opportunities for product innovation, although prescribing depends on patient age, disease stage, tolerability and comorbidities. Payers assess comparative effectiveness, generic availability and formulary impact, while clinicians prioritize symptom control and manageable adverse effects. The fastest-developing commercial opportunities are associated with differentiated mechanisms, improved dosing convenience and therapies designed to complement established levodopa regimens.
United States Parkinson’s Disease Market, By Device and Procedure Type
This dimension covers equipment and procedural technologies purchased by hospitals and specialist centers. Segments include deep brain stimulation systems, focused ultrasound systems, continuous infusion devices, wearable monitoring devices and rehabilitation devices. Deep brain stimulation systems represent the largest established device category due to their clinical history and role in selected patients with advanced motor complications. Adaptive stimulation and focused ultrasound are developing areas, while wearable monitoring and rehabilitation devices support symptom tracking and functional management. Buyers assess clinical evidence, procedural requirements, programming capability, device lifespan, service support and reimbursement. Hospitals also consider operating-room access, specialist training and the cost of follow-up care. Adaptive neuromodulation and connected monitoring represent faster-developing areas because they support individualized treatment and more continuous observation of patient status.
United States Parkinson’s Disease Market, By Disease Stage
Disease-stage segmentation distinguishes early-stage, moderate-stage and advanced-stage patients according to clinical progression and treatment requirements. Early-stage care emphasizes symptom recognition, initial medication selection, education and monitoring. Moderate-stage disease often requires medication adjustment and management of wearing-off or emerging motor complications. Advanced-stage disease generates greater demand for complex medication regimens, continuous infusion, procedural interventions and multidisciplinary support. Moderate-stage patients represent a substantial treatment population because they require ongoing pharmacological management and regular clinical review. Advanced-stage care carries greater treatment intensity and supports demand for device-assisted therapies. Buyers and providers prioritize clinical suitability, functional status, patient preference and caregiver capacity. Earlier diagnosis and improved referral pathways support the expansion of early-stage management, while advanced-stage interventions remain a specialized, higher-complexity commercial category.
United States Parkinson’s Disease Market, By Route of Administration
Route of administration determines how medicines are delivered and influences adherence, convenience, dosing flexibility and treatment suitability. Categories include oral, transdermal, subcutaneous, intrajejunal and other routes. Oral administration remains the largest segment because established Parkinson’s medicines are predominantly prescribed as tablets or capsules. Transdermal delivery provides an alternative for selected patients, while subcutaneous administration supports continuous or intermittent delivery in advanced treatment settings. Intrajejunal delivery serves a specialized patient group requiring continuous levodopa administration. Prescribers consider symptom fluctuations, swallowing difficulties, dosing frequency, patient dexterity and caregiver support. Payers evaluate product cost and treatment setting, while providers consider training and device-management requirements. Subcutaneous and other continuous delivery routes are developing faster as treatment innovation addresses motor fluctuations and limitations associated with conventional oral dosing.
United States Parkinson’s Disease Market, By Patient Age Group
Patient age group is commercially relevant because disease presentation, comorbidity burden, treatment tolerance and care requirements differ across age cohorts. The segments are below 50 years, 50–69 years and 70 years and above. The oldest cohort represents the largest patient group because Parkinson’s prevalence rises with age. Patients in the 50–69-year category form an important treatment population with sustained needs for medication management, employment-related support and long-term functional planning. Below-50 patients represent a smaller but specialized category, often requiring attention to early-onset disease, genetic factors and longer lifetime treatment exposure. Providers tailor therapy according to cognition, mobility, cardiovascular status and other conditions. Earlier-onset diagnosis and precision medicine create developing opportunities in genetic assessment, patient stratification and long-term care planning.
United States Parkinson’s Disease Market, By Care Setting
Care setting distinguishes where diagnosis, treatment, procedures and rehabilitation are delivered. Categories include hospitals, specialty neurology clinics, ambulatory surgical centers, rehabilitation centers and homecare settings. Hospitals remain the largest setting for complex diagnostics, advanced procedures and multidisciplinary management. Specialty neurology clinics are central to routine assessment, medication optimization and longitudinal follow-up. Ambulatory centers support selected procedures, while rehabilitation facilities provide physical, occupational and Speech Therapy. Homecare is an expanding setting for medication support, remote monitoring and caregiver-assisted management. Buyers evaluate specialist availability, equipment requirements, patient travel burden and continuity across care settings. Home-based monitoring and coordinated outpatient care represent faster-developing service models, supported by connected devices and the need to manage chronic disease outside hospital environments.
United States Parkinson’s Disease Market, By Distribution Channel
Distribution channel covers the route through which medicines and selected related products reach patients and care providers. Segments include hospital pharmacies, retail pharmacies, specialty pharmacies and online and mail-order pharmacies. Retail pharmacies remain a major channel for established oral medicines because of broad geographic access and recurring prescription fulfillment. Hospital pharmacies support inpatient treatment, procedural care and specialized therapies, while specialty pharmacies manage complex products that require patient education, handling or adherence support. Online and mail-order channels offer convenience for stable, recurring prescriptions. Buyers assess availability, fulfillment reliability, cold-chain or handling requirements, patient counseling and reimbursement administration. Specialty pharmacy services are developing as advanced therapies require more structured onboarding, training and ongoing support. Distribution performance directly affects treatment continuity and patient experience.
United States Parkinson’s Disease Market, By Payer Type
Payer type identifies the primary funding source for diagnosis and treatment expenditure. Segments include Medicare, Medicaid, commercial insurance, Veterans Affairs and other government programs, and self-pay. Medicare is the largest payer category because Parkinson’s predominantly affects older adults and requires continuing medical management. Medicaid supports eligible patients with limited income and complex care needs, while commercial insurance covers working-age individuals and dependents. Veterans Affairs and other public programs provide care through dedicated healthcare systems. Self-pay represents uncovered expenses, cost sharing and services outside insurance benefits. Providers and manufacturers evaluate coverage criteria, prior authorization, patient affordability and reimbursement consistency. Public payer policy strongly influences access to specialist services, medicines and advanced procedures. Commercial opportunities depend on evidence that supports coverage and sustainable patient access.
| Market Snapshot | Details |
| Market Name | United States Parkinson’s Disease Market |
| Base Year | 2025 |
| Historical Period | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Segmentation | By Diagnosis Type, By Treatment Modality, By Drug Class, By Device and Procedure Type, By Disease Stage, By Route of Administration, By Patient Age Group, By Care Setting, By Distribution Channel, By Payer Type |
| Regions Covered | United States |
| Market Analysis in | Revenue (USD Billion) |
| Market Size (2025) | USD 2.55 Billion |
| Forecast Value (2035) | USD 5.51 Billion |
| CAGR (2026–2035) | 8.0% |
| Company Profiles Covered | 15+ Leading Global Companies |
| Report Coverage | Market Size, Market Share, Growth Analysis, Market Forecast, Value Chain Analysis, Pricing Analysis, Procurement Intelligence, Competitive Landscape, Technology Trends & Regional Insights |
| Report Pages | 250+ Pages |
| Report Format | PDF, Excel Data Pack & PPT |
| Customization | Up to 25% Free Customization |
| Delivery | 24–48 Hours |
| License Options | Single User, Multi User & Enterprise License |
| Analyst Support | One-Year Post-Sales Analyst Support |
| Analyst Contact | [email protected] |
MARKET ANALYSIS REPORT
Strategic Market Snapshot
The United States Parkinson’s Disease Market market combines established pharmaceutical revenue with specialist diagnostics, implantable devices, infusion systems and rehabilitation services. Its commercial structure is shaped by a chronic treatment pathway in which patients move between medication adjustment, specialist evaluation, procedural intervention and supportive care. Established medicines provide recurring utilization, while advanced therapies create differentiated opportunities for manufacturers with strong clinical evidence and provider relationships. Hospitals and neurology centers remain central decision-makers for complex treatment, but pharmacies and payers influence access and continuity. The market’s strategic direction is toward earlier disease characterization, individualized symptom management and connected care. Companies that integrate medicines, devices, diagnostics and patient-support services can strengthen their position across multiple stages of disease management. Market access strategies must address reimbursement, specialist training, affordability and the operational requirements of long-term care.
Value Chain, Cost Structure & Procurement Intelligence
The value chain spans pharmaceutical research and manufacturing, diagnostic technology development, device engineering, clinical validation, distribution, reimbursement and patient support. Medicine costs reflect active ingredients, formulation complexity, manufacturing standards, intellectual property and distribution arrangements. Device procurement adds capital equipment, implantation or procedural costs, software, programming, maintenance and clinical training. Hospitals assess total ownership cost rather than acquisition price alone, particularly for deep brain stimulation and focused ultrasound systems. Procurement cycles involve clinical leadership, neurosurgery or neurology departments, finance, value-analysis committees and supply-chain teams. Pharmaceutical formulary decisions involve pharmacy and therapeutics committees, payers and contracting teams. Implementation complexity rises when therapies require specialist training, patient onboarding or coordination across care settings. Vendors improve competitiveness through predictable supply, clinical education, service responsiveness and evidence supporting operational efficiency.
Market Restraints & Regulatory Challenges
Market expansion faces barriers associated with diagnostic uncertainty, treatment affordability, reimbursement restrictions and uneven access to specialist care. Parkinson’s disease is primarily diagnosed through clinical evaluation, and overlapping symptoms with other neurological conditions complicate early differentiation. Emerging biomarkers and diagnostic technologies require clinical validation and integration into accepted practice. Data privacy requirements apply to connected monitoring devices, patient records and digital care platforms, while device manufacturers must address cybersecurity and software reliability. FDA approval requirements, post-market surveillance and manufacturing quality standards influence product development timelines and commercialization costs. Hospitals also face capital constraints, staffing shortages and procedural capacity limitations. Payer authorization and coverage variation create access friction for advanced therapies. These factors increase commercial risk and favor suppliers with strong clinical evidence, regulatory capabilities and established provider relationships.
Market Opportunities & Outlook 2026–2035
The forecast period creates opportunities across precision diagnosis, differentiated medicines, adaptive neuromodulation and connected patient management. Enterprise AI expansion supports research prioritization, clinical data analysis and the identification of patient subgroups for trials. Workflow automation can improve referral management, medication reconciliation, appointment coordination and longitudinal symptom documentation. Vertical specialization in movement-disorder clinics, neurosurgical centers and specialty pharmacies creates demand for solutions designed around specific clinical workflows. Multilingual patient education and caregiver communication tools can improve access for diverse populations and support treatment adherence. Customer engagement transformation is also relevant to pharmaceutical and device companies, which increasingly require structured patient onboarding, therapy education and post-market feedback. The strongest commercial models connect diagnosis, treatment delivery and ongoing monitoring while demonstrating clinical utility, manageable costs and clear reimbursement pathways.
Country-Level Strategic Insights
The Northeast benefits from established academic medical centers, specialist neurology programs, research institutions and clinical trial infrastructure. Hospitals and research networks in this region support demand for advanced diagnostics, neuromodulation and investigational therapies. Its competitive environment favors companies able to collaborate with specialist centers and demonstrate clinical value.
The Midwest combines large integrated health systems, community neurology practices and established medical technology operations. Demand is shaped by access to specialist care across urban and regional markets, hospital procurement decisions and the need to coordinate long-term treatment. Device suppliers and pharmaceutical companies benefit from strong clinical education and service networks.
The South represents a major commercial region, supported by population growth, older patient cohorts and extensive hospital and outpatient networks. Florida, Texas and other high-population states create demand for neurological services, medication access and rehabilitation. Providers face the operational challenge of connecting specialist care with community and home-based services.
The West is an important center for medical technology innovation, academic research, digital health development and specialized neurological care. California and other western markets support clinical research, advanced device adoption and technology partnerships. Latin America is not part of the US-only market; within the United States, cross-border supply considerations remain relevant for manufacturers and distributors serving national healthcare networks.
Technology, Innovation & Derivative Trends
Technology innovation is shifting Parkinson’s care toward more individualized and connected treatment. Generative AI supports research synthesis, clinical documentation and patient education, while multimodal interaction combines movement data, speech, imaging and patient-reported information to provide a broader view of disease progression. Retrieval-augmented generation can connect clinical decision-support tools with validated medical literature and approved product information, subject to appropriate governance. Conversational analytics supports the interpretation of patient feedback and treatment experience, while connected wearable devices provide additional information about movement patterns and daily function. API interoperability is essential for exchanging information across electronic health records, diagnostic systems, remote monitoring platforms and specialist applications. Enterprise orchestration connects these tools to clinical workflows, but deployment requires privacy safeguards, clinical validation, cybersecurity and human oversight.
Competitive Landscape Overview
Competition spans pharmaceutical manufacturers, medical device companies, diagnostic suppliers and specialist healthcare technology providers. Drug manufacturers differentiate through formulation, mechanism of action, dosing convenience, clinical evidence and payer access. Device companies compete through stimulation accuracy, sensing capability, procedural workflow, programming software and long-term technical support. Diagnostic providers emphasize test reliability, imaging performance, laboratory integration and clinical utility. Pricing structures vary from recurring prescription expenditure to capital equipment purchases, procedural reimbursement and service contracts. Deployment specialization is important because advanced interventions require trained clinicians and dedicated infrastructure. Enterprise partnerships with hospitals, academic research centers and specialty pharmacies support market access and evidence generation. The United States Parkinson’s Disease Market market rewards vendors that combine clinically differentiated products with reliable supply, reimbursement support and comprehensive provider education.
Key Players in the United States Parkinson’s Disease Market
The competitive ecosystem includes pharmaceutical manufacturers, neuromodulation companies, diagnostic technology suppliers and organizations developing emerging treatment approaches. The following companies have relevant marketed products, technologies or research activity across the broader Parkinson’s diagnosis and treatment landscape. Their participation differs by product category and commercial maturity.
- AbbVie Inc.
- Amneal Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences, Inc.
- UCB S.A.
- Lundbeck A/S
- Merz Pharma GmbH & Co. KGaA
- Medtronic plc
- Boston Scientific Corporation
- Abbott Laboratories
- Siemens Healthineers AG
- GE HealthCare Technologies Inc.
- Roche Holding AG
Recent Developments — United States Parkinson’s Disease Market (2025–2026)
Recent developments reflect advances in continuous drug delivery, adaptive neuromodulation, focused ultrasound and investigational disease-modifying approaches. The announcements below demonstrate commercial and clinical activity relevant to the United States market, including regulatory approvals and progression of clinical programs.
- February 2025 — Supernus Pharmaceuticals received FDA approval for ONAPGO, expanding access to continuous subcutaneous apomorphine treatment for motor fluctuations in adults with advanced Parkinson’s disease.
- February 2025 — Medtronic received U.S. FDA approval for BrainSense Adaptive deep brain stimulation, introducing stimulation that adjusts according to detected brain activity.
- January 2025 — AskBio reported the first participants randomized in the Phase II REGENERATE-PD gene therapy trial, advancing clinical development of AB-1005.
- June 2025 — Roche announced plans to advance prasinezumab into Phase III development following evaluation of Phase IIb PADOVA results and longer-term data.
- July 2025 — FDA approval expanded focused ultrasound treatment options for Parkinson’s-related symptoms affecting both sides of the body through staged procedures.
- September 2025 — BlueRock Therapeutics treated the first participant in the pivotal Phase III exPDite-2 trial of investigational cell therapy bemdaneprocel.
- June 2026 — Gain Therapeutics received FDA authorization to advance GT-02287 into Phase II clinical development for Parkinson’s disease.
- September 2026 — AbbVie announced FDA approval of JUVMO (tavapadon), a once-daily selective D1/D5 receptor agonist for adults with Parkinson’s disease.
Methodology & Data Credibility
The market assessment applies bottom-up modeling across diagnostic services, prescription medicines, medical devices and related treatment categories. Revenue estimates are structured by product category, care setting, distribution channel and payer environment to reduce double counting between overlapping clinical pathways. Data triangulation combines company disclosures, regulatory records, clinical trial information, published research, healthcare utilization indicators and market-level benchmarks. Executive interviews with industry participants, clinicians, procurement stakeholders and distribution specialists support interpretation of purchasing behavior and technology adoption. Demand-side validation evaluates patient care pathways, provider requirements and reimbursement conditions, while supply-side validation examines manufacturer portfolios, product availability and commercialization strategies. Cross-region verification tests consistency across national and regional healthcare structures. The approach distinguishes commercial market revenue from the broader economic burden of Parkinson’s disease, which includes indirect costs and unpaid caregiving.
Who Should Read This Report
This report is designed for pharmaceutical and biotechnology executives evaluating product development, portfolio strategy and commercialization opportunities in neurological disorders. Medical device manufacturers can use the analysis to assess neuromodulation, infusion delivery and connected monitoring opportunities. Diagnostic companies gain insight into clinical testing requirements, imaging demand and emerging biomarker pathways. Hospital administrators, neurology department leaders and procurement teams can evaluate technology investment, supplier positioning and care delivery requirements. Investors and financial institutions can use the segmentation and competitive analysis to assess commercial maturity, innovation pathways and market access risks. Payers, specialty pharmacies, distributors and healthcare consultants can apply the findings to reimbursement planning, channel strategy and service development across the United States healthcare ecosystem.
What This Report Delivers
The report delivers a structured assessment of the United States Parkinson’s disease diagnosis and treatment landscape, including market sizing, forecast analysis and commercially relevant segmentation. It evaluates diagnostic methods, treatment modalities, drug classes, devices, disease stages, administration routes, patient cohorts, care settings, distribution channels and payer structures. The analysis examines clinical demand drivers, procurement behavior, reimbursement barriers, regulatory requirements and technology innovation. Competitive coverage identifies companies operating across pharmaceutical, device and diagnostic categories, while recent developments provide context on product approvals and clinical advancement. Regional analysis highlights differences in provider infrastructure and access conditions across the United States. The resulting intelligence supports strategic planning, portfolio prioritization, market entry assessment, investment evaluation, supplier benchmarking and commercial execution.
United States Parkinson’s Disease Market Report Segmentation
By Diagnosis Type
- Clinical and Neurological Assessment
- Structural and Functional Imaging
- Molecular and Biomarker Testing
- Genetic Testing
- Other Diagnostic Tests
By Treatment Modality
- Pharmacological Treatment
- Deep Brain Stimulation
- Focused Ultrasound
- Infusion-Based Therapy
- Supportive and Rehabilitative Care
By Drug Class
- Levodopa Combinations
- Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Amantadine
- Anticholinergics
- Adenosine A2A Receptor Antagonists
- Other Drug Classes
By Device and Procedure Type
- Deep Brain Stimulation Systems
- Focused Ultrasound Systems
- Continuous Infusion Devices
- Wearable Monitoring Devices
- Rehabilitation Devices
By Disease Stage
- Early-Stage
- Moderate-Stage
- Advanced-Stage
By Route of Administration
- Oral
- Transdermal
- Subcutaneous
- Intrajejunal
- Other Routes
By Patient Age Group
- Below 50 Years
- 50–69 Years
- 70 Years and Above
By Care Setting
- Hospitals
- Specialty Neurology Clinics
- Ambulatory Surgical Centers
- Rehabilitation Centers
- Homecare Settings
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Online and Mail-Order Pharmacies
By Payer Type
- Medicare
- Medicaid
- Commercial Insurance
- Veterans Affairs and Other Government Programs
- Self-Pay
| ATTRIBUTES | DETAILS |
|---|---|
|
Market Size (Current)
Current market valuation
|
USD ($) 2.55 USD Billion in 2025 |
|
Market Size (Forecast)
Projected market valuation
|
USD ($) 5.51 USD Billion in 2035 |
|
Growth Rate
Compound Annual Growth Rate
|
CAGR of 8.0% from 2026 to 2035 |
|
Forecast Period
Analysis timeline
|
2026 - 2035 |
|
Base Year
Reference year for analysis
|
2025 |
|
Historical Data Available
Past market data availability
|
2022 - 2024 |
|
Regional Scope
Geographical coverage
|
Global |
|
Segments Covered
Market segments analyzed
|
By Diagnosis Type
By Treatment Modality
By Drug Class
By Device and Procedure Type
By Disease Stage
By Route of Administration
By Patient Age Group
By Care Setting
By Distribution Channel
By Payer Type
|
Key Market Players
Leading companies covered in this report
- AbbVie Inc.
- Amneal Pharmaceuticals
- Inc.
- Supernus Pharmaceuticals
- Inc.
- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences
- Inc.
- UCB S.A.
- Lundbeck A/S
- Merz Pharma GmbH & Co. KGaA
- Medtronic plc
- Boston Scientific Corporation
- Abbott Laboratories
- Siemens Healthineers AG
- GE HealthCare Technologies Inc.
- Roche Holding AG
Frequently Asked Questions
Common questions about this market report.
About the Author
Mrudula Shah
Senior Research Analyst
As a Senior Consultant in Market Research, I help businesses make informed decisions through data analysis. I specialize in secondary and primary research, market estimation. My expertise ensures reliable and actionable market insights.
I hold an M.Sc. in Applied Microbiology from VIT Vellore and a B.Sc. in Microbiology from Fergusson College, Pune. My scientific background enhances my analytical skills in market research.
Passionate about driving business growth, I aim to provide high-quality data and insights.
Detailed Table of Contents
US Parkinson’s Disease Market Segmentation
The global US Parkinson’s Disease Market is segmented based on the following categories, providing a detailed breakdown for comprehensive analysis:
| Segment Category | Segment Values |
|---|---|
| By Diagnosis Type |
|
| By Treatment Modality |
|
| By Drug Class |
|
| By Device and Procedure Type |
|
| By Disease Stage |
|
| By Route of Administration |
|
| By Patient Age Group |
|
| By Care Setting |
|
| By Distribution Channel |
|
| By Payer Type |
|
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects for US Parkinson’s Disease Market. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the US Parkinson’s Disease Market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.